Sponsor
Iambic Therapeutics Inc.
5627 Oberlin Drive Suite 120, 92121-3748, United States
About the sponsor
Research is centered on relapsed/refractory malignancy with documented human epidermal growth factor receptor 2 alterations, reflecting a focused interest in HER2-positive oncology and treatment-resistant disease.
- Relapsed/refractory solid tumours
- HER2-driven cancer biology
- Targeted oncology therapeutics
The clinical activity is directed toward cancers in which HER2 dysregulation plays a defining therapeutic role.
Try clearing a filter, or search the whole catalogue.
Are you running a clinical trial?
Increase visibility for your trials and help patients find your site through our platform.